Last reviewed · How we verify
Calpirinsan (Carbasalate calcium)
Calpirinsan (generic name: Carbasalate calcium) is a carbasalate calcium Small molecule drug developed by UMC Utrecht. It is currently in Phase 2 development.
Calpirinsan works by binding to calcium ions, which are essential for various bodily functions.
Calpirinsan, also known as carbasalate calcium, is a small molecule drug of the carbasalate calcium class. Its exact target and mechanism of action are unknown, but it is believed to work by binding to calcium ions. Calpirinsan is not FDA-approved for any indications, and its commercial status, including patent status and generic availability, is unclear. Further research is needed to determine its safety and efficacy. As a result, key safety considerations and approved indications are currently unavailable.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Carbasalate calcium |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | carbasalate calcium |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Think of calcium ions like keys that unlock many bodily functions, such as muscle contractions and nerve impulses. Calpirinsan acts like a 'key catcher' that binds to these calcium ions, potentially altering their activity. This can have various effects on the body, but the exact nature of these effects is still unknown.
Approved indications
Common side effects
- SARS-CoV-2 sepsis
- Herpes zoster reactivation
- Scrotal pain
- Hypothalamo-pituitary disorder
Key clinical trials
- Anastomotic Leakage Prevention by Endovascular Stenting of the Superior Mesenteric Artery (NA)
- Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation (PHASE2)
- Aspirin in Reduction of Tension II Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calpirinsan CI brief — competitive landscape report
- Calpirinsan updates RSS · CI watch RSS
- UMC Utrecht portfolio CI
Frequently asked questions about Calpirinsan
What is Calpirinsan?
How does Calpirinsan work?
Who makes Calpirinsan?
What is the generic name of Calpirinsan?
What drug class is Calpirinsan in?
What development phase is Calpirinsan in?
What are the side effects of Calpirinsan?
Related
- Drug class: All carbasalate calcium drugs
- Manufacturer: UMC Utrecht — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing